FGEN earnings call for the period ending March 31, 2019.
News & Analysis: FibroGen
The company reported confusing top-line results from an important batch of phase 3 safety studies. Were they successful?
April's about to shower biopharma investors with important updates that could move these stocks.
FGEN earnings call for the period ending December 31, 2018.
Even though the market fell, these stocks gained ground. Find out why.
Positive phase 2 data for the company's lung drug increases the biotech's value.
The biotech makes a stock offering at a good price.
Are you looking to put money to work in the biotech sector? Here are three stocks our contributors like right now.